RNA, U6 small nuclear 88, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-88P profile across patient tissues and cancer cell-line models. RNU6-88P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RNU6-88P is differentially expressed in 10, with the highest sampling consensus in UCEC. Additionally, RNU6-88P RNA expression shows 16,568 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, UCEC, and DLBC as cancer lineages where RNU6-88P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-88P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-88P survival associations across molecular data types. RNU6-88P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-88P RNA expression–survival associations across cancer types. High RNU6-88P expression shows unfavorable associations in KIRC, but favorable associations in SKCM, UCS, READ, ACC and LUSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SKCM as the clearest survival context for RNU6-88P RNA expression.
This table summarizes RNU6-88P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-88P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-88P shows lower tumor expression in THCA and higher tumor expression in UCEC, KIRC, LUSC, HNSC and BLCA. The UCEC box plot shows higher RNU6-88P RNA expression in tumor versus normal tissue (log2 FC = +1.474, t-test p < 0.001).
This table shows molecular features associated with RNU6-88P in patient tissues and cancer cell lines. In patient samples, RNU6-88P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
